MARKET

EVFM

EVFM

Evofem Bioscienc
OTCMQB
0.012
-0.000
-2.54%
Closed 15:07 07/26 EDT
OPEN
0.011
PREV CLOSE
0.012
HIGH
0.012
LOW
0.0096
VOLUME
561.24K
TURNOVER
5.97K
52 WEEK HIGH
196.25
52 WEEK LOW
0.0060
MARKET CAP
713.69K
P/E (TTM)
-0.0019
1D
5D
1M
3M
1Y
5Y
1D
Evofem Biosciences Expands Global Reach and Secures Funding
TipRanks · 3d ago
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
UAE contraceptive drug market is projected to reach $185.1 million by 2030. Pharma 1 anticipates filing UAE regulatory submission for Phexxi as a hormone-free contraceptive in Q3 2024. Evofem Biosciences, Inc. And Pharma 1 Drug Store LLC have signed a license agreement for the Middle East rights to PheXXi. Phe xxi is the first and only FDA-approved contraceptive gel approved for use in the UAE.
PR Newswire · 3d ago
Weekly Report: what happened at EVFM last week (0715-0719)?
Weekly Report · 4d ago
Evofem Biosciences Enhances Investor Communication Strategy
TipRanks · 07/18 12:52
Why Is Aditxt (ADTX) Stock Up 72% Today!
Aditxt and Evofem Biosciences merger is expected to be completed by the end of September. Aditxt stock is up 71.7% as of Wednesday morning. Shares of Gabelli Multimedia Trust Rights (GGTr) are up 110% this morning.
Investorplace · 07/17 12:23
Aditxt And Evofem Amend Merger Agreement, Aiming For September 30 Closure; Evofem Acquires FDA-Approved SOLOSEC
Aditxt and Evofem are working to close the contemplated transaction in the second half of 2024. The closing of the transaction remains subject to the successful satisfaction of a number of closing conditions. The amended and restated Merger Agreement addresses pre-closing issues.
Benzinga · 07/17 10:36
*Aditxt And Evofem Are Diligently Working to Close Contemplated Transaction in 2H of 2024 >ADTX
Dow Jones · 07/17 10:32
*Aditxt: Revisions Include Substituting Cash for Aditxt's Common Stk as Consideration for Evofem's Common Stk in Merger >ADTX
Dow Jones · 07/17 10:31
More
About EVFM
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is commercializing advanced products to address unmet needs in women’s sexual and reproductive health. Its first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Using its platform, women can have a telehealth visit with a health care provider to determine their eligibility for a Phexxi prescription. It is also focused on commercializing SOLOSEC (secnidazole) 2g oral granules that address two pervasive sexual health infections.

Webull offers Evofem Biosciences Inc stock information, including OTCMQB: EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.